FY2029 Earnings Forecast for ABUS Issued By HC Wainwright

Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) - HC Wainwright issued their FY2029 EPS estimates for shares of Arbutus Biopharma in a research note issued to investors on Wednesday, February 26th. HC Wainwright analyst E. Arce forecasts that the biopharmaceutical company will earn $0.29 per share for the year. HC Wainwright has a "Buy" rating and a $5.00 price objective on the stock. The consensus estimate for Arbutus Biopharma's current full-year earnings is ($0.39) per share.

A number of other brokerages have also recently issued reports on ABUS. StockNews.com cut shares of Arbutus Biopharma from a "hold" rating to a "sell" rating in a research note on Tuesday, February 25th. JMP Securities increased their price target on shares of Arbutus Biopharma to $5.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $5.00 target price (up previously from $4.50) on shares of Arbutus Biopharma in a report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $5.50.

Arbutus Biopharma Stock Down 0.9 %

Shares of NASDAQ:ABUS traded down $0.03 during trading on Thursday, reaching $3.42. The stock had a trading volume of 1,310,112 shares, compared to its average volume of 1,010,814. Arbutus Biopharma has a 52 week low of $2.30 and a 52 week high of $4.73. The firm has a market capitalization of $648.06 million, a price-to-earnings ratio of -7.95 and a beta of 1.78. The stock has a fifty day simple moving average of $3.32 and a two-hundred day simple moving average of $3.66.

Remove Ads

Hedge Funds Weigh In On Arbutus Biopharma

Several institutional investors have recently added to or reduced their stakes in ABUS. Charles Schwab Investment Management Inc. raised its position in Arbutus Biopharma by 218.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,212,246 shares of the biopharmaceutical company's stock valued at $4,667,000 after buying an additional 831,663 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Arbutus Biopharma during the third quarter worth approximately $754,000. Barclays PLC boosted its holdings in Arbutus Biopharma by 466.3% during the 3rd quarter. Barclays PLC now owns 272,029 shares of the biopharmaceutical company's stock valued at $1,047,000 after acquiring an additional 223,995 shares during the period. State Street Corp boosted its holdings in shares of Arbutus Biopharma by 50.2% during the third quarter. State Street Corp now owns 4,407,133 shares of the biopharmaceutical company's stock worth $16,967,000 after purchasing an additional 1,472,652 shares during the period. Finally, Wellington Management Group LLP boosted its holdings in Arbutus Biopharma by 4.6% in the third quarter. Wellington Management Group LLP now owns 496,818 shares of the biopharmaceutical company's stock valued at $1,913,000 after acquiring an additional 21,807 shares in the last quarter. 43.79% of the stock is owned by institutional investors and hedge funds.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.